COVID-19 and RSV Flashcards

1
Q

outbreak

A

-illness happens in unexpected high numbers
-may stay in one area or extend more widely
-can last days or years
-if disease is unknown, new to population, or absent for long time 1 single case is considered an outbreak

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

epidemic / pandemic

A

-infectious disease spreads quickly to more people expected
-affects a larger area than outbreak

-pandemicis outbreak that spreads across countries or continents
-affects more people and takes more lives than epidemic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

of lives lost in pandemic depends on

A

-How many people are infected
-How severe of an illness the virus causes (its virulence)
-How vulnerable certain groups of people are
-Prevention efforts and how effective they are

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

flu pandemic: spanish flu 1918

A

-Death Toll: 20 -50 million
-Cause: Influenza
-1918-1920
-deadly outbreak
-global 1/3+ of world’s population
-ending the lives of 675,000 in U.S, 50 million people worldwide
-mortality rate- 10%-20%, with up to 25 million deaths in the first 25 weeks alone
-What separated the 1918 flu pandemic from other influenza -> killed healthy young adults, while leaving children and those with weaker immune systems alive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

the black death (1346-1353)

A

-Death Toll: 75 – 200 million
-Cause: Bubonic Plague
-From 1346 to 1353
-outbreak in Europe, Africa, and Asia,
-death toll- 75 - 200 million
-originated in Asia, spread via fleas living on rats that lived on merchant ships
-bacteria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

COVID-19 as of 2024

A

-global #- 702,529,440
-global death- 6,974,972
-US confirmed- 110,791,717
-US deaths- 1,193,867

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Coronaviruses (CoV)

A

-large family of viruses
-can cause illness in animals or humans
-humans- respiratory infections
from common cold to more severe like severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and coronavirus disease 2019 (COVID-19)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

COVID-19 emergence

A

-Identified in Wuhan, China in December 2019
-COVID-19 is caused by the virus SARS-CoV-2
-Early in the outbreak, many patients were reported to have a link to a large seafood and live animal market
-Later, no link to the market indicating person-to-person spread of the disease
-Travel-related exportation of cases reported

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

COVID-19 transmission

A

-aerosols- <5um diameter
-suspended in air- >1m distance
-contact/droplet- >5um diameter direct contact OR <1m distance
-fomites?
-points of entry- eyes, nose, mouth
-Person-to-person
considered predominant mode of transmission, likely via respiratory droplets from coughing, sneezing, singing, talking, or breathing
-High-level viral shedding evident in upper respiratory tract
-Airborne transmission suggested by multiple studies, but frequency unclear in absence of aerosol-generating procedures in healthcare settings
-virus rarely cultured in respiratory samples > 9 days after symptom onset, especially in patients with mild disease
-Multiple studies describe a correlation between reduced infectivity with decreases in viral loads and rises in neutralizing antibodies
-ACOG: “Data indicate that vertical transmission appears to be uncommon”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

nonpharmacologic preventative intervention: COVID-19

A

-Inactivation of SARS-CoV, MERS-CoV, and other endemic human coronaviruses readily accomplished with 62% to 71% ethanol, 0.5% hydrogen peroxide, or 0.1% sodium hypochlorite (in 1 min)[5]
-0.05% to 0.2% benzalkonium chloride, 0.02% chlorhexidine digluconate less effective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

COVID-19 symptoms

A

-symptoms may appear 2-14 days after exposure to virus
-congestion or runny nose
-new loss of taste or smell
-fatigue, muscle or body aches
-fever or chills
-headache
-cough sore throat
-SOB or difficulty breathing
-nausea or vomiting, diarrhea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

COVID-19 extrapulmonary manifestations

A

-derm- petechiae, liveido reticularis, erythematous rash, urticaria, vesicles, pernio-like lesions
-cardiac- takotsubo cardiomyopathy, myocardial injury/myocarditis, cardiac arrhythmias, cardiogenic shock, myocardial ischemia, acute cor pulmonale
-endocrine- hyperglycemia, diabetic ketoacidosis
-GI- diarrhea, nausea/vomiting, abdominal pain, anorexia
-neurologic- headaches, dizziness, encephalopathy, guillain barre, ageusia, myalgia, anosmia, stroke
-thromboembolism- DVT, pulmonary embolism, catheter related thrombosis
-hepatic- elevated ALT/AST, elevated bilirubin
-renal- acute kidney injury, proteinuria, hematuria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

stages of COVID-19

A

-asymptomatic or presymptomatic infection- + test but no symptoms
-mild illness- varied symptoms but NO SOB, dyspnea, abnormal imaging
-moderate illness- SpO2 > 94% and lower respiratory disease evidenced by clinical assessment or imaging
-severe illness- SpO2 < 94%, PaO2/FiO2 <300, respiratory rate > 30, or lung infiltrates > 50%
-critical illness- respiratory failure, septic shock, and/or multiorgan dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

stages and tx: COVID

A

-stage 1 (early stage)- mild constitution symptoms, dry cough, lymphopenia
-stage 2 (pulmonary phase)- SOB without hypoxia, abnormal chest imaging, transaminitis, low normal procalcitonin
-stage 3 hyperinflammation phase- ARDS, SIRS/shock, cardiac failure, elevated inflammatory markers (CRP, LDH, IL-6, D-dimer, ferritin), troponin, NT-proBNP elevation
-tx for stage 2 and 3- remdesivir (not used for stage 3), dexamethasone, O2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

COVID-19 people at higher risk for severe illness

A

-In some cases seriously illness -> develop difficulty breathing -> death
-risk factors:
-age
-underlying medical conditions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

COVID-19 dx

A

-outpt point of care rapid PCR testing in 15 mins
-coronavirus SARS Cov2
-human rhinovirus
-influenza A virus
-influenza B virus
-respiratory syncytial virus

17
Q

COVID-19 respiratory viral panels

A

-virus:
-Coronavirus SARS Cov2 RNA
-Human Rhinovirus/Enterovirus RNA
-Influenza A Virus RNA
-Influenza B Virus RNA
-Respiratory Syncytial Virus RNA
-Adenovirus DNA
-Coronavirus HKU1, NL63, 229E, OC43 RNA
-Human Metapneumovirus RNA
-Parainfluenza Virus 1, 2, 3, 4 RNA

-bacteria:
-Mycoplasma Pneumoniae DNA
-Chlamydophila Pneumoniae DNA
-Bordetella Parapertussis DNA
-Bordetella Pertussis DNA

18
Q

non-therapeutic management of MILD COVID-19

A

-WHO:
-isolate suspected/confirmed cases at home, designated COVID-19 health or community facility
-treat symptoms
-educate pt

-NIH:
-majority cases managed in ambulatory setting or at home (by telemedicine)
-no imaging or lab indicated if otherwise healthy
-close monitor older pts and pts with underlying conditions
-non-hospitalized pts do not initiate anticoagulants or antiplatelet therapy to prevent VTE or arterial thrombosis unless other indications exist

19
Q

guidance on thomboprophylaxis

A

-NIH:
-hospitalized adults should get VTE prophylaxis per SoC for other hospitalized adults
-anticoagulant or antiplatelet therapy should not be used to prevent arterial thrombosis outside of usual SoC for pt without COVID-19
-hospitalized pts should not be routinely discharged on VTE prophylaxis (extended VTE prophylaxis considered in pts with low bleeding risk and high VTE Risk)

-ASH:
-all hospitalized adults with COVID-19 should have thromboprophylaxis with low molecular weight heparin over unfractionated heparin unless bleeding risk outweights thrombosis risk
-fondaparinux is recommended in setting of heparin induced thrombocytopenia
-in pts whom anticoagulants are contraindicated or unavailable -> use mechanical thromboprophylaxis
-encourage participation on clinical trails rather than empiric use of therapeutic dose heparin in COVID-19 pts with no other indication for therapeutic dose anticoagulation

20
Q

respiratory viruses in general

A

-are cause of large % of all COPD exacerbations
-in pts with underling cardiac disease respiratory viruses can play major role in triggering both ischemic events and CHF exacerbations
-are trigger for large % of asthma exacerbations

21
Q

respiratory viral panel: ID wide variety of pathogens now

A

-virus:
-Coronavirus SARS Cov2 RNA
-Human Rhinovirus/Enterovirus RNA
-Influenza A Virus RNA
-Influenza B Virus RNA
-Respiratory Syncytial Virus RNA
-Adenovirus DNA
-Coronavirus HKU1, NL63, 229E, OC43 RNA
-Human Metapneumovirus RNA
-Parainfluenza Virus 1, 2, 3, 4 RNA

-bacteria:
-Mycoplasma Pneumoniae DNA
-Chlamydophila Pneumoniae DNA
-Bordetella Parapertussis DNA
-Bordetella Pertussis DNA

22
Q

respiratory syncytial virus (RSV)

A

-RSV is common virus that infects nose, throat, and lungs
-Spreads via contact with respiratory droplets (coughing, sneezing, or kissing) OR touching surfaces contaminated with the virus and then touching your eyes, nose, or mouth.
-Survives for many hours on hard surfaces
-survives on soft surfaces such as tissues and hands for shorter amounts of time

23
Q

who is at risk for RSV

A

-Almost all kids will have RSV by age 2.
-Can lead to severe illness among both children and certain adults.
-80% of children younger than age 2 years who are hospitalized for an RSV illness do not have risk factors
-Adults in the US: estimated to cause 60,000-160,000 hospitalizations and 6,000-10,000 deaths in age 65 years and older annually

24
Q

risk factors for developing severe disease from RSV

A

-severe disease: pneumonia, asthma, COPD exacerbation

-Cardiopulmonary disease (eg, COPD, asthma, CHF, CAD) -> high hospitalization
-Kidney disease
-Liver disease
-Diabetes mellitus
-Chronic or progressive neurologic or neuromuscular conditions
-Moderate to severe immunocompromise
-Hematologic disorders
-Frailty
-Advanced age or premature infant

25
Q

symptoms in adults: RSV

A

-Incubation: 4-6 days
-runny nose, coughing, sneezing, fever, and decreased appetite
-In many cases, virus progresses to lower respiratory tract, and symptoms such as cough, wheezing, and dyspnea can develop
-Some pts may develop severe disease (eg, pneumonia and respiratory failure)
-Can be asymptomatic and transmit it to others

26
Q

RSV: dx and tx

A

-Dx: Included in the respiratory panel
-Treatment: supportive, +/- steroids, bronchodilators
-Prevention: vaccination, ages 60 and older, pregnant women between 32-36 weeks or after birth

27
Q

RSV vs influenza: impact on adults aged 65+

A

-RSV:
-2.2 mil pts
-177,000 hospitalized
-14,000 die
-RSV is more common than flu and covid- 2024

-flu:
-1.4-5.1 mil pts
-128,467,000 hospitalized
-12,000-43,000